Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 17, 2026
TickeronGET DAILY SIGNALS
Why Is SELLAS Life Sciences Group (SLS) Stock Up +157.03% Today?

Why Is SELLAS Life Sciences Group (SLS) Stock Up +157.03% Today?

Key Takeaways

  • SLS shares surged 157.03%, or $11.73, to $19.20 in Monday-afternoon-style fashion on Tuesday, after a pivotal leukemia trial delivered the answer investors had waited more than a year for.
  • The primary catalyst was topline data from the Phase 3 REGAL trial of galinpepimut-S (GPS), an investigational cancer vaccine that met its primary overall survival endpoint in acute myeloid leukemia (AML).
  • GPS patients reached a median overall survival of 24.0 months versus 14.7 months on best available treatment, a 41% reduction in the risk of death, with no new safety signals reported.
  • Secondary drivers: management intends to meet the FDA about an accelerated filing pathway and is preparing a Biologics License Application in the first half of 2027, while the readout also validates the broader WT1-targeted platform.
  • Broader market context was hostile — biotech exchange-traded funds and small-cap benchmarks were lower on the session — confirming the move was entirely company-specific rather than sector-driven.
  • News Significance Score: 96/100 — Transformative pivotal trial win met an extraordinarily rare, enormous price move on record volume.
  • Traders are watching FDA feedback on the accelerated pathway, the full dataset presentation, and SLS009 data at the American Society of Hematology meeting in December.
  • Investors can dig deeper into Price Targets, Earnings, and Forecast pages for additional detail on the name.
  • For systematic, rules-based exposure to names like this, explore Trending AI Robots.

Opening Summary

SELLAS Life Sciences Group, Inc. (SLS) is a late-stage clinical biopharmaceutical company developing immunotherapies and small-molecule drugs for hematologic and solid-tumor cancers. Its lead asset is galinpepimut-S (GPS), a WT1-targeted cancer vaccine licensed from Memorial Sloan Kettering Cancer Center, alongside tambiciclib (SLS009), a CDK9 inhibitor.

In Tuesday's session, the stock traded at $19.20 as of the afternoon, up $11.73, or 157.03%, from the prior session's close of $7.47. The direction was unmistakably upward. Shares opened at $24.11, reached a session high near $24.89, and cooled to a low around $16.70 before stabilizing — a violent open followed by heavy profit-taking. The immediate reason cited by markets was the positive Phase 3 REGAL readout, a genuinely binary event for the company.

Catalyst Breakdown: A Pivotal Trial Win

The REGAL trial tested GPS as maintenance monotherapy in AML patients who had achieved a second or later complete remission after salvage therapy and who were ineligible for, or unable to undergo, a stem cell transplant — a population with few good options. The study met its primary endpoint of overall survival, with a statistically significant and clinically meaningful improvement over investigator-selected best available treatment.

Median overall survival of 24.0 months versus 14.7 months is a wide separation for a single-agent, off-the-shelf immunotherapy compared against physician-chosen combinations of hypomethylating agents, venetoclax, or low-dose cytarabine. The 41% reduction in risk of death, absent new safety concerns, is the kind of result that supports a registrational filing rather than a repeat study. For a company with no approved product and no revenue, that distinction is the entire investment case.

Regulatory Path and Pipeline Read-Through

Management said it will meet the FDA to discuss an accelerated filing strategy and is preparing a Biologics License Application for GPS in the first half of 2027, alongside manufacturing and launch-readiness work. The company also framed the result as Phase 3 validation of its WT1-targeted technology, a protein overexpressed across roughly 20 tumor types, which broadens the perceived opportunity well beyond AML.

The secondary program, SLS009, adds optionality: preliminary topline data from an 80-patient Phase 2 trial in newly diagnosed AML are expected in the fourth quarter, and completed Phase 2 results in relapsed or refractory disease will be presented at the ASH annual meeting on December 12–15. Neither program was the reason for today's move, but both reinforce the narrative.

Market Context and Trading Activity

Volume was extraordinary: more than 109 million shares changed hands against a three-month average of roughly 6.5–6.9 million, an order of magnitude above normal turnover. The buying was not borrowed from the sector — biotech exchange-traded funds slipped between 0.5% and 0.6%, and small-cap benchmarks fell about 1.4% — so the divergence from the tape was near-total.

Technically, the gap left the stock far above every recent reference level. Shares had spent November grinding between roughly $7.50 and $9.00 after a months-long decline from August highs near $15.50, so the open near $24 cleared the entire prior range in a single print. The fade from the intraday high toward $19 reflects aggressive profit-taking into a market capitalization now near $3.9 billion, up from roughly $1.5 billion the day before.

News Significance Score

The scale runs from 0, meaning no meaningful news and a move that is routine for the stock, to 100, meaning transformative news paired with an extreme and rare price move. The verified news here is about as strong as clinical-stage biotech news gets: a pivotal Phase 3 trial hitting its primary survival endpoint with a wide margin, unlocking a filing pathway. The price behavior was equally extreme, roughly 35 times the stock's typical absolute daily move of about 4.4%, and no session in the prior 60 came close to a move of this size. Those two components combine to 96 out of 100.

What Comes Next for SLS

Attention turns to the FDA meeting and the timeline for a BLA submission, the disclosure of the complete dataset — including secondary endpoints, subgroup analyses, and immunologic correlates — at a major medical conference, and publication in a peer-reviewed journal. The ASH presentation in December and the SLS009 Phase 2 topline data expected this quarter are the next scheduled catalysts.

Analyst coverage remains thin, with a single Buy rating and a bullish long-term view that today's rally has already partly closed. Risks are substantial: regulatory timing can slip, the full dataset may reveal narrower benefit in subgroups, manufacturing scale-up for a biologic is capital-intensive, and a company with a $134.7 million cash position as of September 30 and a widening net loss may need to raise capital again. There is no guarantee of approval.

Trending AI Robots

Tickeron offers hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers under current market conditions earn a place in the curated Trending AI Robots section. Bots differ widely by strategy, timeframe, performance metrics, and the symbols they trade, so the lineup shifts as market conditions change. Reviewing the current leaders is a practical way to see how automated strategies are adapting to today's volatility.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SLS

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


SLS in downward trend: price expected to drop as it breaks its higher Bollinger Band on November 17, 2026

SLS broke above its upper Bollinger Band on November 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 53 similar instances where the stock broke above the upper band. In 47 of the 53 cases the stock fell afterwards. This puts the odds of success at 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SLS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

The Aroon Indicator for SLS entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 60 cases where SLS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.

The Momentum Indicator moved above the 0 level on November 17, 2026. You may want to consider a long position or call options on SLS as a result. In 79 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.

The Moving Average Convergence Divergence (MACD) for SLS just turned positive on November 17, 2026. Looking at past instances where SLS's MACD turned positive, the stock continued to rise in 36 of 41 cases over the following month. The odds of a continued upward trend are 88%.

SLS moved above its 50-day moving average on November 17, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +8.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where SLS advanced for three days, in 240 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.352) is normal, around the industry mean (3.592). P/E Ratio (-38.273) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. SLS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 43 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -4%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was -24%. SLS experienced the highest price growth at 113%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 19%. For the same stocks of the Industry, the average monthly volume growth was -10% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of biopharmaceuticals

Industry Biotechnology

Industry
Biotechnology
Address
7 Times Square
Phone
+1 646 200-5278
Employees
13
Web
https://www.sellaslifesciences.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.
KLAR dropped -4.84% to $13.75 from Wednesday's close of $14.45, with the decline occurring during Thursday's regular session. JPMorgan downgraded the shares to Hold from Overweight and cut its price target to $17 from $20 in a note published before the open, extending a run of post-earnings target reductions.
CBRS fell -6.07% to $97.86 in the opening minutes of Wednesday's regular session, down from Tuesday's close of $104.18 — the move occurred during market hours, not premarket or after-hours. No verified news or fundamental catalyst found: no new filing, contract, or analyst action explains the drop, which is likely continued give-back from the post-earnings pop and the stock's habitual volatility — CBRS has averaged a ±4.5% daily swing over the past 60 sessions, and 17 of those sessions moved as much or more.
Why Is SELLAS Life Sciences Group (SLS) Stock Up +157.03% Today?